Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TWi Biotechnology has announced that it has received Notice of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from United States Patent & Trademark Office (USPTO) for patent application U.S. 13/533,271 entitled, "Methods of decreasing glycosylated hemoglobin in patients with dyslipidemia" and U.S. 13/414,264 entitled, "Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia".
Subscribe to our email newsletter
These two patents broadly cover methods and uses for AC-201 as monotherapy or in combination with other lipid lower agents to treat patients with type II diabetes and dyslipidemiaor patients with hyperuricemia, respectively. These patents are parts of TWi Biotechnology’s broad intellectual property portfolio for AC-201.
"We are very pleased with the issuance of these patents in United States for AC-201. These new issuances provide TWi Biotechnology the intellectual property protection for AC-201 addressing unmet medical needs as an effective treatment for type II diabetes and hyperuricemia," said Dr. Calvin C. Chen, President of TWi Biotechnology.
Currently, type II diabetic patients with dyslipidemia are mostly recommended to manage their lipid profile with HMG-CoA reductase inhibitors (statins). However, labels on statins for dyslipidemia treatment in the United States now include information concerning glycemic effects, including diabetes and increases in hemoglobin A1c (HbA1c) or fasting plasma glucose (FPG).
"This new issuance of patent application U.S. 13/533,271 provides TWi Biotechnology the intellectual property protection for AC-201 address an underserved with an effective treatment for patients who have both type II diabetes and dyslipidemia," said Dr. Chen.
AC-201 has demonstrated its efficacy of reducing HbA1c levels in type II diabetic patients in two phase II clinical trials. TWi Biotechnology last year presented the results of a 259-patient multinational phase IIb study at the American Diabetes Association 73rd Scientific Sections in Chicago, USA.
Added Dr. Chen: "The other new issuance of patent application U.S. 13/414,264 is an important addition to our existing patent portfolio and strengthens our ability to protect our proprietary method of use of AC-201 for hyperuricemia and gout treatment. We continue to work towards a planned phase II trial of AC-201 for gout treatment in Q3 2014."
AC-201 is a first-in-class, orally available small molecule which has shown the ability to inhibit the production and activity of caspase-1 and the cytokine Interleukin-1Beta (IL-1Beta),and to down-regulate IL-1Beta receptors.
Inhibition of IL-1Beta signaling has been demonstrated to be effective in treating a variety of diseases including arthritis, gout, and diabetes mellitus (DM). The active ingredient of AC-201 has been approved for treating patients with chronic rheumatic diseases in France and subsequently in other EU and Middle Eastern countries such as Spain and Italy since mid-1990.
TWi Biotechnology holds two US INDs for AC-201 — one for controlling blood glucose in patients with type II diabetes and the other for treating gout in patients under taking urate-lowering therapy.
In addition to the good safety record of its active ingredient used in treating another chronic disease, AC-201 has undergone testing in several human clinical trials including 3 phase II trials with up to 6 months treatment period with a satisfactory safety profile demonstrated.